http://orcid.org/0000-0002-0597-829X
References
- Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839.
- Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–580.
- Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016;351:1166–1171.
- Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951;11:480–493.
- Bates SR, Rothblat GH. Regulation of cellular sterol flux and synthesis by human serum lipoproteins. Biochim Biophys Acta. 1974;360:38–55.
- Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–2393.
- Ritsch A, Scharnagl H, Marz W. HDL cholesterol efflux capacity and cardiovascular events. N Engl J Med. 2015;372:1870–1871.
- Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851–860.
- Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–1795.
- Stegemann C, Pechlaner R, Willeit P, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129:1821–1831.
- Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.
- Crosby J, Peloso GM, et al; TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
- Timpson NJ, Walter K, Min JL, et al., Members UOC. A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nat Comm. 2014;5:4871.
- Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–436.
- Pechlaner R, Tsimikas S, Yin X, et al. Very-low density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of apoC-III. J Am Coll Cardiol. 2017;69:789–800.
- van Capelleveen JC, Bernelot Moens SJ, Yang X, et al. Apolipoprotein C-III levels and incident coronary artery disease risk: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2017;37:1206–1212.